RE:No questionsI'm not sure, but it may only have been available to "registered" shareholders and not anyone logging in as a guest. THe registration process, I was told, was burdensome. I just logged in as a guest.
On the plus side they confirmed the new TH1902 protocol was submitted in early May, there's a number of changes in it to optimize efficacy (at least 3 they listed and we know) and they will host a science call to review what changed and why -which I think is very important to understand and allow investors to handicap it better. By then the lead investigator will have also presented that 1a data in a paper, so a lot of hard facts to fill in the holes, whether good or bad.
Once again mentioned the oncology program will be looking to accellerate talks to potential interested parties in multiple areas, not just one. I have to assume the lead is working with the immunology part, but maybe also something around the carboplatin combo or the stem cell/VM anti-metastatic combo pre-clinical they showed. If they can get there, it would be valuable to have multiple legs to stand on around this and then do the same for something with SN38 and SiRNA - move those talks along and broaden them way, way out. Then they'll actually start looking something like a Bicycle, Sutro, SeaGen and others ---even Cybrexa has their first partner. It's not easy, but any validation would do wonders to re-insert pipeline value.
One thing I'm still confused about is whether they will actually enroll some TH1902 patients to finish off 1b on their own, with money budgeted for it, or if they will just get the approval and then look for a means or partner to do that. Whether it's some sort of gov't grant or whether they already paid that and had that RD in the past budget, sort of accrued, to ending 1b or not is hard to tell. The stage-gating talk and EBITDA breakeven and seeking enrollees isn't clear to me at this point. I suppose it may only be discussed at that science meeting and what their next steps will be. If I were them, I'd try to find a way to cut $2mil somewhere and use that to finish 1b and get another set of data with the new protocol. At some point they'll clear that up, and maybe I'm just missing something in my understanding and interpreting their language around it. Eventually we'll find out.
FYI-- A very interesting Gilead acquisition today. Bought a pre-clinical oncology company (so pre-clinical work can be valuable) in the hot area of PARP1 for oncology. Was slated to go to clinic in 2023. They think it would be a very good combo with Trodelvy. The name of the company was close, but not close enought --XinThera!. Undisclosed payment, but there is an active market for targeted combo approaches which is sort of a cheap way for large companies to keep rolling out expanded franchises if they work. You don't necessarily have to buy and can just partner, but guess they liked the pre-clinical and maybe was in the <$100 range so they just gobbled it up. THere's 3 Parp1 versions and some other inflammation drugs all in pre-clinical. Upfront and milestone payments structure.